How I treat acute venous thromboembolism in patients with brain tumors

2.

Simanek

R

,

Vormittag

R

,

Hassler

M

, et al.

Venous thromboembolism and survival in patients with high-grade glioma

.

Neuro Oncol

.

2007

;

9

(

2

):

89

-

95

.

3.

Mulder

FI

,

Candeloro

M

,

Kamphuisen

PW

, et al.

The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis

.

Haematologica

.

2019

;

104

(

6

):

1277

-

1287

.

4.

Veiga

VC

,

Peres

SV

,

Ostolin

T

, et al.

Incidence of venous thromboembolism and bleeding in patients with malignant central nervous system neoplasm: systematic review and meta-analysis

.

PLoS One

.

2024

;

19

(

6

):

e0304682

.

5.

Riedl

J

,

Preusser

M

,

Nazari

PMS

, et al.

Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism

.

Blood

.

2017

;

129

(

13

):

1831

-

1839

.

6.

Zwicker

JI

,

Liebman

HA

,

Neuberg

D

, et al.

Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy

.

Clin Cancer Res

.

2009

;

15

(

22

):

6830

-

6840

.

7.

Geddings

JE

,

Mackman

N

.

Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients

.

Blood

.

2013

;

122

(

11

):

1873

-

1880

.

8.

Khorana

AA

,

Mackman

N

,

Falanga

A

, et al.

Cancer-associated venous thromboembolism

.

Nat Rev Dis Primers

.

2022

;

8

(

1

):

11

.

9.

Agnelli

G

,

Becattini

C

,

Meyer

G

, et al.

Apixaban for the treatment of venous thromboembolism associated with cancer

.

N Engl J Med

.

2020

;

382

(

17

):

1599

-

1607

.

10.

Raskob

GE

,

van Es

N

,

Verhamme

P

, et al.

Edoxaban for the treatment of cancer-associated venous thromboembolism

.

N Engl J Med

.

2018

;

378

(

7

):

615

-

624

.

11.

Young

AM

,

Marshall

A

,

Thirlwall

J

, et al.

Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)

.

J Clin Oncol

.

2018

;

36

(

20

):

2017

-

2023

.

12.

Agnelli

G

,

Becattini

C

,

Meyer

G

, et al.

Apixaban for the treatment of venous thromboembolism associated with cancer

.

N Engl J Med

.

2020

;

382

(

17

):

1599

-

1607

.

13.

Planquette

B

,

Bertoletti

L

,

Charles-Nelson

A

, et al.

Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial

.

Chest

.

2022

;

161

(

3

):

781

-

790

.

14.

McBane

RD

,

Wysokinski

WE

,

Le-Rademacher

JG

, et al.

Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial

.

J Thromb Haemost

.

2020

;

18

(

2

):

411

-

421

.

15.

Schrag

D

,

Uno

H

,

Rosovsky

R

, et al.

Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial

.

JAMA

.

2023

;

329

(

22

):

1924

-

1933

.

16.

Lyman

GH

,

Carrier

M

,

Ay

C

, et al.

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

.

Blood Adv

.

2021

;

5

(

4

):

927

-

974

.

17.

Khorana

AA

,

Kuderer

NM

,

Culakova

E

,

Lyman

GH

,

Francis

CW

.

Development and validation of a predictive model for chemotherapy-associated thrombosis

.

Blood

.

2008

;

111

(

10

):

4902

-

4907

.

18.

Key

NS

,

Khorana

AA

,

Kuderer

NM

, et al.

Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline update

.

J Clin Oncol

.

2020

;

38

(

5

):

496

-

520

.

19.

Key

NS

,

Khorana

AA

,

Kuderer

NM

, et al.

Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline update

.

J Clin Oncol

.

2023

;

41

(

16

):

3063

-

3071

.

20.

Iyengar

V

,

Agrawal

S

,

Chiasakul

T

, et al.

Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review

.

J Thromb Haemost

.

2024

;

22

(

2

):

423

-

429

.

21.

Zwicker

JI

,

Karp Leaf

R

,

Carrier

M

.

A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation

.

J Thromb Haemost

.

2016

;

14

(

9

):

1736

-

1740

.

22.

Bosnjak

R

,

Derham

C

,

Popović

M

,

Ravnik

J

.

Spontaneous intracranial meningioma bleeding: clinicopathological features and outcome

.

J Neurosurg

.

2005

;

103

(

3

):

473

-

484

.

23.

Ehret

F

,

Kaul

D

,

Mose

L

, et al.

Intracranial hemorrhage in patients with anticoagulant therapy undergoing stereotactic radiosurgery for brain metastases: a bi-institutional analysis

.

Cancers

.

2022

;

14

(

3

):

465

.

24.

Ghia

AJ

,

Tward

JD

,

Anker

CJ

,

Boucher

KM

,

Jensen

RL

,

Shrieve

DC

.

Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control

.

J Radiosurg SBRT

.

2014

;

3

(

1

):

43

-

50

.

25.

Carney

BJ

,

Uhlmann

EJ

,

Puligandla

M

, et al.

Anticoagulation after intracranial hemorrhage in brain tumors: risk of recurrent hemorrhage and venous thromboembolism

.

Res Pract Thromb Haemost

.

2020

;

4

(

5

):

860

-

865

.

26.

Samuelson Bannow

BT

,

Lee

A

,

Khorana

AA

, et al.

Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH

.

J Thromb Haemost

.

2018

;

16

(

6

):

1246

-

1249

.

27.

Iyengar

V

,

Patell

R

,

Ren

S

, et al.

Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation

.

Blood Adv

.

2023

;

7

(

24

):

7516

-

7524

.

28.

Patell

R

,

Hsu

C

,

Shi

M

, et al.

Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer

.

Haematologica

.

2024

;

109

(

6

):

1849

-

1856

.

29.

Ianosi

B

,

Gaasch

M

,

Rass

V

, et al.

Early thrombosis prophylaxis with enoxaparin is not associated with hematoma expansion in patients with spontaneous intracerebral hemorrhage

.

Eur J Neurol

.

2019

;

26

(

2

):

333

-

341

.

30.

Ma

S

,

Patell

R

,

Miller

E

, et al.

Antiplatelet medications and intracranial hemorrhage in patients with primary brain tumors

.

J Thromb Haemost

.

2023

;

21

(

5

):

1148

-

1155

.

31.

Miller

EJ

,

Patell

R

,

Uhlmann

EJ

, et al.

Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors

.

Blood Adv

.

2022

;

6

(

5

):

1559

-

1565

.

32.

Yang

L

,

Chen

CJ

,

Guo

XL

, et al.

Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis

.

J Neuro Oncol

.

2018

;

137

(

1

):

49

-

56

.

33.

Norden

AD

,

Bartolomeo

J

,

Tanaka

S

, et al.

Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients

.

J Neuro Oncol

.

2012

;

106

(

1

):

121

-

125

.

34.

Donato

J

,

Campigotto

F

,

Uhlmann

EJ

, et al.

Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study

.

Blood

.

2015

;

126

(

4

):

494

-

499

.

35.

McKenzie

G

,

Gaskins

J

,

Rattani

A

, et al.

Radiosurgery fractionation and post-treatment hemorrhage development for intact melanoma brain metastases

.

J Neuro Oncol

.

2022

;

160

(

3

):

591

-

599

.

36.

Giustozzi

M

,

Proietti

G

,

Becattini

C

,

Roila

F

,

Agnelli

G

,

Mandalà

M

.

ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis

.

Blood Adv

.

2022

;

6

(

16

):

4873

-

4883

.

37.

Zoga

E

,

Wolff

R

,

Ackermann

H

, et al.

Factors associated with hemorrhage of melanoma brain metastases after stereotactic radiosurgery in the era of targeted/immune checkpoint inhibitor therapies

.

Cancers (Basel)

.

2022

;

14

(

10

):

2391

.

38.

Lesueur

P

,

Kao

W

,

Leconte

A

, et al.

Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial

.

BMC Cancer

.

2020

;

20

(

1

):

147

.

39.

Kim

SS

,

Kim

SM

,

Park

M

,

Suh

SH

,

Ahn

SJ

.

Clinico-radiological features of brain metastases from thyroid cancer

.

Medicine (Baltimore)

.

2021

;

100

(

48

):

e28069

.

40.

Pouessel

D

,

Culine

S

.

High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor

.

Eur Urol

.

2008

;

53

(

2

):

376

-

381

.

41.

Chevreau

C

,

Ravaud

A

,

Escudier

B

, et al.

A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases

.

Clin Genitourin Cancer

.

2014

;

12

(

1

):

50

-

54

.

42.

Xing

W

,

He

X

,

Kassir

MA

, et al.

Evaluating hemorrhage in renal cell carcinoma using susceptibility weighted imaging

.

PLoS One

.

2013

;

8

(

2

):

e57691

.

43.

Mandybur

TI

.

Intracranial hemorrhage caused by metastatic tumors

.

Neurology

.

1977

;

27

(

7

):

650

-

655

.

44.

Motzer

RJ

,

Bosl

GJ

.

Hemorrhage: a complication of metastatic testicular choriocarcinoma

.

Urology

.

1987

;

30

(

2

):

119

-

122

.

45.

Mantia

C

,

Uhlmann

EJ

,

Puligandla

M

,

Weber

GM

,

Neuberg

D

,

Zwicker

JI

.

Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin

.

Blood

.

2017

;

129

(

25

):

3379

-

3385

.

46.

Kim

SS

,

Lee

S

,

Park

M

,

Joo

B

,

Suh

SH

,

Ahn

SJ

.

Associated factors of spontaneous hemorrhage in brain metastases in patients with lung adenocarcinoma

.

Cancers (Basel)

.

2023

;

15

(

3

):

619

.

47.

Lee

V

,

Jairam

V

,

Yu

JB

,

Park

HS

.

Nationwide patterns of hemorrhagic stroke among patients hospitalized with brain metastases: influence of primary cancer diagnosis and anticoagulation

.

Sci Rep

.

2020

;

10

(

1

):

10084

.

48.

Xiao

B

,

Wang

W

,

Zhang

D

.

Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials

.

OncoTargets Ther

.

2018

;

11

:

5059

-

5074

.

49.

Falanga

A

,

Leader

A

,

Ambaglio

C

, et al.

EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer

.

Hemasphere

.

2022

;

6

(

8

):

e750

.

50.

Bikdeli

B

,

Caraballo

C

,

Trujillo-Santos

J

, et al.

Clinical presentation and short- and long-term outcomes in patients with isolated distal deep vein thrombosis vs proximal deep vein thrombosis in the RIETE Registry

.

JAMA Cardiol

.

2022

;

7

(

8

):

857

-

865

.

51.

Le Gal

G

,

Kovacs

MJ

,

Bertoletti

L

, et al.

Risk for recurrent venous thromboembolism in patients with subsegmental pulmonary embolism managed without anticoagulation: a multicenter prospective cohort study

.

Ann Intern Med

.

2022

;

175

(

1

):

29

-

35

.

52.

Kirkilesis

G

,

Kakkos

SK

,

Bicknell

C

,

Salim

S

,

Kakavia

K

.

Treatment of distal deep vein thrombosis

.

Cochrane Database Syst Rev

.

2020

;

4

(

4

):

Cd013422

.

53.

Ageno

W

,

Bertù

L

,

Bucherini

E

, et al.

Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial

.

BMJ

.

2022

;

379

:

e072623

.

54.

Galanaud

JP

,

Trujillo-Santos

J

,

Bikdeli

B

, et al.

Clinical presentation and outcomes of patients with cancer-associated isolated distal deep vein thrombosis

.

J Clin Oncol

.

2024

;

42

(

5

):

529

-

537

.

55.

Mahajan

A

,

Brunson

A

,

Eldredge

J

,

White

RH

,

Keegan

THM

,

Wun

T

.

Incidence and outcomes associated with 6,841 isolated distal deep vein thromboses in patients with 13 common cancers

.

Thromb Haemost

.

2022

;

122

(

8

):

1407

-

1414

.

56.

Girardi

L

,

Ciuffini

LA

,

Mai

V

, et al.

Risk of recurrent venous thromboembolism and bleeding in patients with acute isolated subsegmental pulmonary embolism

.

Thromb Res

.

2024

;

239

:

109037

.

57.

Ageno

W

,

Haas

S

,

Weitz

JI

, et al.

Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE Registry

.

Thromb Haemost

.

2019

;

119

(

8

):

1365

-

1372

.

58.

Bleker

SM

,

van Es

N

,

Kleinjan

A

, et al.

Current management strategies and long-term clinical outcomes of upper extremity venous thrombosis

.

J Thromb Haemost

.

2016

;

14

(

5

):

973

-

981

.

59.

Carney

BJ

,

Uhlmann

EJ

,

Puligandla

M

, et al.

Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors

.

J Thromb Haemost

.

2019

;

17

(

1

):

72

-

76

.

60.

Leader

A

,

Hamulyák

EN

,

Carney

BJ

, et al.

Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases

.

Blood Adv

.

2020

;

4

(

24

):

6291

-

6297

.

61.

Candeloro

M

,

Eikelboom

JW

,

Chan

N

,

Bhagirath

V

,

Douketis

JD

,

Schulman

S

.

Carbamazepine, phenytoin, and oral anticoagulants: drug-drug interaction and clinical events in a retrospective cohort

.

Res Pract Thromb Haemost

.

2022

;

6

(

2

):

e12650

.

62.

Perlman

A

,

Wanounou

M

,

Goldstein

R

,

Choshen Cohen

L

,

Singer

DE

,

Muszkat

M

.

Ischemic and thrombotic events associated with concomitant Xa-inhibiting direct oral anticoagulants and antiepileptic drugs: analysis of the FDA Adverse Event Reporting System (FAERS)

.

CNS Drugs

.

2019

;

33

(

12

):

1223

-

1228

.

63.

Galgani

A

,

Palleria

C

,

Iannone

LF

, et al.

Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs

.

Front Neurol

.

2018

;

9

:

1067

.

64.

Goldstein

R

,

Rabkin

N

,

Buchman

N

, et al.

The effect of levetiracetam compared with enzyme-inducing antiseizure medications on apixaban and rivaroxaban peak plasma concentrations

.

CNS Drugs

.

2024

;

38

(

5

):

399

-

408

.

65.

Ostrowski

RP

,

He

Z

,

Pucko

EB

,

Matyja

E

.

Hemorrhage in brain tumor – an unresolved issue

.

Brain Hemorrhages

.

2022

;

3

(

2

):

98

-

102

.

66.

Heit

JJ

,

Iv

M

,

Wintermark

M

.

Imaging of intracranial hemorrhage

.

J Stroke

.

2017

;

19

(

1

):

11

-

27

.

67.

Weerink

LB

,

Appelman

AP

,

Kloet

RW

,

Van der Hoorn

A

.

Susceptibility-weighted imaging in intracranial hemorrhage: not all bleeds are black

.

Br J Radiol

.

2023

;

96

(

1148

):

20220304

.

68.

Reed-Guy

L

,

Desai

AS

,

Phillips

RE

, et al.

Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: a retrospective cohort study

.

Neuro Oncol

.

2022

;

24

(

12

):

2172

-

2179

.

69.

Boeer

A

,

Voth

E

,

Henze

T

,

Prange

HW

.

Early heparin therapy in patients with spontaneous intracerebral haemorrhage

.

J Neurol Neurosurg Psychiatry

.

1991

;

54

(

5

):

466

-

467

.

70.

Faust

AC

,

Finch

CK

,

Hurdle

AC

,

Elijovich

L

.

Early versus delayed initiation of pharmacological venous thromboembolism prophylaxis after an intracranial hemorrhage

.

Neurol

.

2017

;

22

(

5

):

166

-

170

.

71.

Byrnes

MC

,

Irwin

E

,

Roach

R

,

James

M

,

Horst

PK

,

Reicks

P

.

Therapeutic anticoagulation can be safely accomplished in selected patients with traumatic intracranial hemorrhage

.

World J Emerg Surg

.

2012

;

7

(

1

):

25

.

72.

Matsushima

K

,

Inaba

K

,

Cho

J

, et al.

Therapeutic anticoagulation in patients with traumatic brain injury

.

J Surg Res

.

2016

;

205

(

1

):

186

-

191

.

73.

Barnes

JA

,

Goodney

PP

.

Evidence supporting the use of inferior vena cava filters in patients with cancer-coming into focus

.

JAMA Netw Open

.

2020

;

3

(

7

):

e2011942

.

74.

Edwin

NC

,

Khoury

MN

,

Sohal

D

,

McCrae

KR

,

Ahluwalia

MS

,

Khorana

AA

.

Recurrent venous thromboembolism in glioblastoma

.

Thromb Res

.

2016

;

137

:

184

-

188

.

75.

Balabhadra

S

,

Kuban

JD

,

Lee

S

, et al.

Association of inferior vena cava filter placement with rates of pulmonary embolism in patients with cancer and acute lower extremity deep venous thrombosis

.

JAMA Netw Open

.

2020

;

3

(

7

):

e2011079

.

76.

Quezada

A

,

Jiménez

D

,

Bikdeli

B

, et al.

Outcomes after vena cava filter use in patients with cancer-associated venous thromboembolism and contraindications to anticoagulation

.

Thromb Haemost

.

2020

;

120

(

7

):

1035

-

1044

.